JASCAYD® (nerandomilast) approved in Japan, advancing global access to a new IPF and PPF treatment
🤖 D.R.A.F.T. Summary
Not intended for UK and US audiences JASCAYD® (nerandomilast) now approved by Japan’s MHLW for the treatment of adults with idiopathic pulmonary fibrosis and adults with progressive pulmonary fibrosis Approval enables access to the first oral PDE4B inhibitor with antifibrotic and immunomodulatory effects authorized for use in IPF and PPF, and the first new treatment in... The post JASCAYD® (nerandomilast) approved in Japan, advancing global access to a new IPF and PPF treatment appeared first on Montreal Gazette.
Outlets covering this story
Financial Post
LEFT
Montreal Gazette
LEFT
2 of 5 perspectives covered — limited perspective range
Side-by-Side Outlet Comparison — Starter+
See how 2 outlets framed this story — bias by source, F.A.C.T. framing analysis, and verdict side by side.
Unlock with Starter →